Freestone Capital Holdings’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$32.9M Sell
27,406
-231
-0.8% -$236K 0.85% 22
2026
Q1
$25.4M Sell
27,637
-902
-3% -$914K 0.77% 22
2025
Q4
$30.7M Buy
28,539
+1,384
+5% +$1.32M 0.91% 19
2025
Q3
$20.7M Sell
27,155
-271
-1% -$202K 0.63% 27
2025
Q2
$21.4M Buy
27,426
+1,318
+5% +$1.02M 0.72% 22
2025
Q1
$21.6M Sell
26,108
-1,501
-5% -$1.25M 0.8% 20
2024
Q4
$21.3M Buy
27,609
+855
+3% +$708K 0.74% 22
2024
Q3
$23.7M Buy
26,754
+189
+0.7% +$170K 0.81% 19
2024
Q2
$24.1M Buy
26,565
+227
+0.9% +$182K 0.86% 18
2024
Q1
$20.5M Buy
26,338
+1,531
+6% +$1.09M 0.76% 20
2023
Q4
$14.5M Buy
24,807
+439
+2% +$256K 0.65% 28
2023
Q3
$13.1M Sell
24,368
-321
-1% -$165K 0.69% 27
2023
Q2
$11.6M Buy
24,689
+783
+3% +$328K 0.47% 39
2023
Q1
$8.21M Sell
23,906
-2,130
-8% -$718K 0.36% 48
2022
Q4
$9.52M Sell
26,036
-1,205
-4% -$427K 0.44% 43
2022
Q3
$8.81M Sell
27,241
-4,857
-15% -$1.54M 0.4% 38
2022
Q2
$10.4M Sell
32,098
-3,075
-9% -$923K 0.4% 39
2022
Q1
$10.1M Buy
35,173
+588
+2% +$151K 0.4% 54
2021
Q4
$9.55M Buy
34,585
+1,360
+4% +$345K 0.4% 51
2021
Q3
$7.68M Sell
33,225
-25
-0.1% -$6.17K 0.39% 59
2021
Q2
$7.63M Buy
33,250
+7,427
+29% +$1.49M 0.38% 63
2021
Q1
$4.82M Buy
25,823
+196
+0.8% +$38.3K 0.26% 93
2020
Q4
$4.33M Sell
25,627
-22,797
-47% -$3.4M 0.25% 89
2020
Q3
$7.17M Sell
48,424
-729
-1% -$113K 0.47% 50
2020
Q2
$8.07K Buy
49,153
+27,480
+127% +$4.22M 0.09% 45
2020
Q1
$3.01K Sell
21,673
-1,241
-5% -$171K 0.07% 107
2019
Q4
$3.01K Buy
22,914
+550
+2% +$63.8K 0.06% 137
2019
Q3
$2.5K Sell
22,364
-12
-0.1% -$1.34K 0.06% 156
2019
Q2
$2.48K Buy
22,376
+1,105
+5% +$130K 0.06% 144
2019
Q1
$2.76M Sell
21,271
-2,089
-9% -$254K 0.16% 144
2018
Q4
$2.7M Sell
23,360
-2,537
-10% -$283K 0.18% 135
2018
Q3
$2.78M Sell
25,897
-1,686
-6% -$169K 0.02% 150
2018
Q2
$2.35M Buy
27,583
+267
+1% +$21.9K 0.01% 153
2018
Q1
$2.11M Buy
27,316
+901
+3% +$72.5K 0.12% 147
2017
Q4
$2.23M Buy
26,415
+618
+2% +$52.6K 0.15% 143
2017
Q3
$2.21M Buy
25,797
+262
+1% +$21.5K 0.16% 135
2017
Q2
$2.1M Buy
25,535
+339
+1% +$27.7K 0.16% 136
2017
Q1
$2.12M Buy
25,196
+1,404
+6% +$112K 0.16% 140
2016
Q4
$1.75M Buy
23,792
+1,272
+6% +$94.7K 0.15% 140
2016
Q3
$1.81M Sell
22,520
-2,127
-9% -$170K 0.17% 131
2016
Q2
$1.94M Buy
24,647
+346
+1% +$26K 0.19% 119
2016
Q1
$1.75M Sell
24,301
-3,293
-12% -$249K 0.18% 107
2015
Q4
$2.33M Buy
27,594
+2,099
+8% +$174K 0.24% 67
2015
Q3
$2.13M Buy
+25,495
New +$2.15M 0.23% 67
2013
Q3
Sell
-8,713
Closed -$428K 384
2013
Q2
$428K Buy
+8,713
New +$474K 0.09% 211

Other funds holding LLY

Freestone Capital Holdings's LLY Position: Q2 2026 in Review

Freestone Capital Holdings reduced its Eli Lilly (LLY) stake by 0.84% in Q2 2026, selling an estimated $236K and leaving 27,406 shares worth $32.9M. The position accounts for 0.85% of the portfolio, ranked #22.

Freestone Capital Holdings first reported a position in LLY in Q2 2013 and has held it in 45 quarters since. 4,599 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Freestone Capital Holdings held 27,406 shares of Eli Lilly worth $32.9M as of Q2 2026.
  • Freestone Capital Holdings sold 231 Eli Lilly shares in Q2 2026, an estimated $236K.
  • Eli Lilly made up 0.85% of Freestone Capital Holdings's portfolio in Q2 2026, its #22 holding.
  • Freestone Capital Holdings first reported a position in Eli Lilly in Q2 2013 and has held it in 45 quarters since.
  • 4,599 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Freestone Capital Holdings's 13F filing for Q2 2026, filed 31 Jul 2026.